https://sciex.com/content/SCIEX/na/us/en


Fast, Efficient, Disulfide Bond Mapping Using BioPharmaView™ Software

May 11, 2016 | Biopharma, Blogs | 0 comments

Fast LC-MS acquisition and automated data processing will help you speed up peptide mapping of your biotherapeutic, including critical disulfide bond and post-translational modification characterization. SCIEX helps you untangle the complexity of disulfide bonds, speeding up your characterization process.

  • High-resolution, accurate mass MS, and MS/MS information from the SCIEX TripleTOF® 5600+ and 6600 Systems provide the data necessary to differentiate closely related species and confirm structural assignments.
  • Confirm your molecule’s disulfide bond pattern more quickly using BioPharmaView™ software, which utilizes automated peak assignment and scoring.
  • The combination of the TripleTOF Systems and BioPharmaView Software simplifies data processing and reporting, reducing overall processing time for accurate disulfide bond assignment. 

See the full article by downloading the compendium >

Accurate disulfide bond mapping is essential for correctly establishing structure-function relationships as well as for monitoring the structural integrity of recombinant monoclonal antibodies (mAbs) throughout their production. Inappropriate disulfide bonds can affect a mAb’s stability, potency, aggregation, and may also signal errors in the cell culture or purification process. By following a biotherapeutic’s disulfide patterns over time, manufacturers can quickly detect production problems and then correct them as early as possible.

Correctly assigning disulfide bonds in a mAb, or ADC can be challenging and time-consuming due to the heterogeneity, large size, and multiple cysteine residues found in these biomolecules. Traditional approaches for disulfide mapping are based on fast liquid chromatography-mass spectrometry (LC-MS) analysis; however, these methods can be inefficient and usually involve digestion with multiple enzymes, tedious data processing, and intensive manual inspection of chromatograms for the identification of any possible disulfide linkages.

As the biotherapeutics industry develops and expands, there is an urgent need for software tools that can rapidly facilitate and accelerate the higher-order structural characterization of biopharmaceutical products. To meet these requirements, SCIEX has developed BioPharmaView™ Software, a data processing suite that can reduce the complexity of the massive data sets generated during biotherapeutic analysis. BioPharmaView Software uses rapid processing tools to accelerate critical characterization assays–such as peptide mapping and disulfide bond identification– by automating peak assignments, simplifying data processing, and streamlining the reporting process.

Peak Assignment Reduces Time for Peptide Mapping Experiments
To identify and match peptides, BioPharmaView Software automatically scores b- and y- ions from the high-resolution MS/MS spectra; and then the highest scoring experimental peaks are compared to a list of theoretical masses automatically generated by the software. The peak assignment process is further enhanced by predicting the theoretical fragment ion masses for non-reduced, disulfide-linked peptides before comparison with experimental data. Including other criteria in the ion selection process–such as MS/MS scoring, multiple charge states, and a retention time (RT) filter–can also help reduce the time needed for peptide mapping experiments. This enables manufacturers to meet regulatory requirements more quickly during the production and marketing of a new biotherapeutic product.

The Results
In this article, we successfully developed an efficient and automated workflow that comprehensively identified every disulfide linkage in the Fab region of an mAb. The use of the high-speed, TripleTOF® LC-MS System contributed to time-savings during disulfide analysis by permitting accurate mass MS and MS/MS information to be collected simultaneously, providing the high-resolution data necessary for differentiating closely related species and confirming structural assignments. And by using BioPharmaView Software to process the dataset, identifying the location of five disulfide linkages in the Fab region of an mAb was completed in a fast and automated fashion.

See the results in the full article by downloading the Biologics Analytical Characterization Compendium >

Questions and answers to help improve your mycotoxin analysis

During a recent webinar I shared method details for mycotoxin analysis on the SCIEX 7500 system. In this blog i will share the Q&A for the submitted questions that we did not have chance to answer during the live webinar.

A 2-fold revolution: MS approaches for the bioanalysis of oligonucleotide therapeutics

In 1998, the US Food and Drug Administration (FDA) approved fomivirsen as the first therapeutic oligonucleotide therapeutic. This approval marked a revolution of mechanism of action discovered decades before finally coming to fruition. Since then, the landscape of chemical modifications of oligonucleotides, conjugations and formulations has evolved tremendously, contributing to improvements in stability, efficacy and safety. Today, more than a dozen antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) drugs are on the market, most of which are designated as orphan drugs for treating rare genetic diseases.

Is “right first time, every time” a pipedream for metabolite identification by LC-MS?

If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery.

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial